TP53 and non-small cell lung carcinoma: We have initially reported that WBSCR22 knockdown attenuates the sensitivity of non-small cell lung cancer cell lines H460, harboring wild type p53, to 7-Ethyl-10-hydroxycamptothecin (SN-38; the active metabolite of camptothecin) and 5-fluorouracil (5-FU), but not in p53-null H1299 cells30.